Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
ConditionKnee Arthritis
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age40-75
SponsorNYU Langone Health
About this trial
The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.
Eligibility criteria
Qualifiers
Patients presenting with knee osteoarthritis (KL Grade II-III)
Knee pain for at least three months, occurring in at least half of the days in that period
VAS ≥ 4
Patients ages 40-75, inclusive
Disqualifiers
Knee Injections within the last 3 months (cortisone, PRP, hyaluronic acid)
Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
Younger than 40 years of age
Older than 75 years of age
Trial design
Treatments tested in this trial
- Cannabidiol (CBD)
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
NYU Langone Health
Lead sponsor
Orcosa Inc.
Collaborator
Source ClinicalTrials.gov